yttrium-90 anti-Tac antibody

**Yttrium-90 anti-Tac antibody** is an investigational CD25-directed radioimmunoconjugate developed at the National Cancer Institute. It consists of murine IgG2a anti-Tac monoclonal antibody labeled with the pure beta-emitting radionuclide yttrium-90. Anti-Tac binds the alpha subunit of the high-affinity interleukin-2 receptor, CD25, concentrating beta radiation at CD25-expressing malignant T cells and thereby causing localized radiotoxic injury. It was evaluated intravenously in Tac-expressing adult T-cell leukemia/lymphoma and cutaneous T-cell lymphoma, including a completed Phase 1 NCI study using multidose administration. This murine product is distinct from the later humanized anti-Tac radioimmunoconjugate 90Y-HAT. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/2238051/))

Other names

90Y-anti-Tacyttrium-90-labeled anti-Tac antibodyyttrium90-labeled anti-Tac antibodyyttrium 90-labeled anti-Tac antibodyyttrium-90 radiolabeled anti-Tacyttrium90 radiolabeled anti-Tacyttrium 90 radiolabeled anti-Tac